User login
Key clinical point: Both rituximab and glatiramer acetate failed to stop disability progression in patients with secondary progressive multiple sclerosis (SPMS). They were equally effective in relapse control.
Major finding: The mean Expanded Disability Status Scale (EDSS) score increased from 3.05 to 4.14 in the rituximab group and from 3.22 to 4.60 in the glatiramer acetate group (P less than .001 for both). EDSS score showed no statistically significant difference between 2 groups (P = .071). Annualized relapse rate decreased in both groups with no significant difference between them (P = .534).
Study details: An open randomized clinical trial of 84 patients with SPMS assigned to receive rituximab (n = 43) or glatiramer acetate (n = 41) for 12 months.
Disclosures: The study was funded by vice-chancellor for research and technology of Isfahan University of Medical Sciences. The authors declared no conflicts of interest.
Citation: Cheshmavar M et al. Acta Neurol Scand. 2020 Sep 8. doi: 10.1111/ane.13344.
Key clinical point: Both rituximab and glatiramer acetate failed to stop disability progression in patients with secondary progressive multiple sclerosis (SPMS). They were equally effective in relapse control.
Major finding: The mean Expanded Disability Status Scale (EDSS) score increased from 3.05 to 4.14 in the rituximab group and from 3.22 to 4.60 in the glatiramer acetate group (P less than .001 for both). EDSS score showed no statistically significant difference between 2 groups (P = .071). Annualized relapse rate decreased in both groups with no significant difference between them (P = .534).
Study details: An open randomized clinical trial of 84 patients with SPMS assigned to receive rituximab (n = 43) or glatiramer acetate (n = 41) for 12 months.
Disclosures: The study was funded by vice-chancellor for research and technology of Isfahan University of Medical Sciences. The authors declared no conflicts of interest.
Citation: Cheshmavar M et al. Acta Neurol Scand. 2020 Sep 8. doi: 10.1111/ane.13344.
Key clinical point: Both rituximab and glatiramer acetate failed to stop disability progression in patients with secondary progressive multiple sclerosis (SPMS). They were equally effective in relapse control.
Major finding: The mean Expanded Disability Status Scale (EDSS) score increased from 3.05 to 4.14 in the rituximab group and from 3.22 to 4.60 in the glatiramer acetate group (P less than .001 for both). EDSS score showed no statistically significant difference between 2 groups (P = .071). Annualized relapse rate decreased in both groups with no significant difference between them (P = .534).
Study details: An open randomized clinical trial of 84 patients with SPMS assigned to receive rituximab (n = 43) or glatiramer acetate (n = 41) for 12 months.
Disclosures: The study was funded by vice-chancellor for research and technology of Isfahan University of Medical Sciences. The authors declared no conflicts of interest.
Citation: Cheshmavar M et al. Acta Neurol Scand. 2020 Sep 8. doi: 10.1111/ane.13344.